Heartland Group Holdings Limited

HGH.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HGH.AX stands at 935.8M. In comparison, AFG.AX has a market cap of 494.6M. Regarding current trading prices, HGH.AX is priced at A$0.99, while AFG.AX trades at A$1.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HGH.AX currently has a P/E ratio of 14.14, whereas AFG.AX's P/E ratio is 12.13. In terms of profitability, HGH.AX's ROE is +0.07%, compared to AFG.AX's ROE of +0.19%. Regarding short-term risk, HGH.AX is less volatile compared to AFG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.AX.Check AFG.AX's competition here

HGH.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HGH.AX stands at 935.8M. In comparison, RMC.AX has a market cap of 354M. Regarding current trading prices, HGH.AX is priced at A$0.99, while RMC.AX trades at A$0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HGH.AX currently has a P/E ratio of 14.14, whereas RMC.AX's P/E ratio is 7.46. In terms of profitability, HGH.AX's ROE is +0.07%, compared to RMC.AX's ROE of +0.13%. Regarding short-term risk, HGH.AX is less volatile compared to RMC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.AX.Check RMC.AX's competition here

HGH.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HGH.AX stands at 935.8M. In comparison, D13.AX has a market cap of 22.3M. Regarding current trading prices, HGH.AX is priced at A$0.99, while D13.AX trades at A$0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HGH.AX currently has a P/E ratio of 14.14, whereas D13.AX's P/E ratio is -2.05. In terms of profitability, HGH.AX's ROE is +0.07%, compared to D13.AX's ROE of -1.54%. Regarding short-term risk, HGH.AX is more volatile compared to D13.AX. This indicates potentially higher risk in terms of short-term price fluctuations for HGH.AX.Check D13.AX's competition here

HGH.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HGH.AX stands at 935.8M. In comparison, YBR.AX has a market cap of 20M. Regarding current trading prices, HGH.AX is priced at A$0.99, while YBR.AX trades at A$0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HGH.AX currently has a P/E ratio of 14.14, whereas YBR.AX's P/E ratio is -6.10. In terms of profitability, HGH.AX's ROE is +0.07%, compared to YBR.AX's ROE of -0.09%. Regarding short-term risk, HGH.AX is less volatile compared to YBR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.AX.Check YBR.AX's competition here

HGH.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HGH.AX stands at 935.8M. In comparison, N1H.AX has a market cap of 8.8M. Regarding current trading prices, HGH.AX is priced at A$0.99, while N1H.AX trades at A$0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HGH.AX currently has a P/E ratio of 14.14, whereas N1H.AX's P/E ratio is 10.00. In terms of profitability, HGH.AX's ROE is +0.07%, compared to N1H.AX's ROE of +0.48%. Regarding short-term risk, HGH.AX is more volatile compared to N1H.AX. This indicates potentially higher risk in terms of short-term price fluctuations for HGH.AX.Check N1H.AX's competition here